The historic rise of Viagra has firmly established as a example of pharmaceutical success, yet its position within the broader industry now raises questions about long-term yields . Alternative versions are eroding market share, causing worries that investing in companies heavily reliant to Viagra's previous position could be a dangerous strategy,